PLoS ONE (Jan 2015)

Interleukin 6 receptor is an independent prognostic factor and a potential therapeutic target of ovarian cancer.

  • Aki Isobe,
  • Kenjiro Sawada,
  • Yasuto Kinose,
  • Chifumi Ohyagi-Hara,
  • Erika Nakatsuka,
  • Hiroshi Makino,
  • Tomonori Ogura,
  • Tomoko Mizuno,
  • Noriko Suzuki,
  • Eiichi Morii,
  • Koji Nakamura,
  • Ikuko Sawada,
  • Aska Toda,
  • Kae Hashimoto,
  • Seiji Mabuchi,
  • Tsuyoshi Ohta,
  • Ken-ichirou Morishige,
  • Hirohisa Kurachi,
  • Tadashi Kimura

DOI
https://doi.org/10.1371/journal.pone.0118080
Journal volume & issue
Vol. 10, no. 2
p. e0118080

Abstract

Read online

Ovarian cancer remains the most lethal gynecologic cancer and new targeted molecular therapies against this miserable disease continue to be challenging. In this study, we analyzed the expressional patterns of Interleukin-6 (IL-6) and its receptor (IL-6R) expression in ovarian cancer tissues, evaluated the impact of these expressions on clinical outcomes of patients, and found that a high-level of IL-6R expression but not IL-6 expression in cancer cells is an independent prognostic factor. In in vitro analyses using ovarian cell lines, while six (RMUG-S, RMG-1, OVISE, A2780, SKOV3ip1 and OVCAR-3) of seven overexpressed IL-6R compared with a primary normal ovarian surface epithelium, only two (RMG-1, OVISE) of seven cell lines overexpressed IL-6, suggesting that IL-6/IL-6R signaling exerts in a paracrine manner in certain types of ovarian cancer cells. Ovarian cancer ascites were collected from patients, and we found that primary CD11b+CD14+ cells, which were predominantly M2-polarized macrophages, are the major source of IL-6 production in an ovarian cancer microenvironment. When CD11b+CD14+ cells were co-cultured with cancer cells, both the invasion and the proliferation of cancer cells were robustly promoted and these promotions were almost completely inhibited by pretreatment with anti-IL-6R antibody (tocilizumab). The data presented herein suggest a rationale for anti-IL-6/IL-6R therapy to suppress the peritoneal spread of ovarian cancer, and represent evidence of the therapeutic potential of anti-IL-6R therapy for ovarian cancer treatment.